Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr
Biopharma Acquisitions Biopharma merger and acquisition value for the second quarter of 2022 reached $25.4bn from 36 transactions, 20 of which had disclosed values. Four M&A transactions hit or exceed
US FDA wants to work with all stakeholders and developers of cardiac troponin assays to increase the availability of such tests that work, according to agency reviewer Paula Capisino. Capisino, from F
US FDA is holding a public workshop in November to discuss challenges and best practices with the development of cardiac troponin assays. The Nov. 28 meeting at the agency's Silver Spring, Md., he